Back to Journals » Patient Preference and Adherence » Volume 2

Reasons for noncompliance with five-yearly screening flexible sigmoidoscopy

Authors Viiala CH, Olynyk JK

Published 30 October 2008 Volume 2008:2 Pages 27—33


Charlie Henri Viiala, John Kevin Olynyk

School of Medicine and Pharmacology, Fremantle Hospital, University of Western Australia, Perth, Western Australia, Australia

Objective: To determine factors influencing the low return rate observed in a program of flexible sigmoidoscopy for average risk screening for colorectal carcinoma.

Methods: Flexible sigmoidoscopy-based screening of average risk 55–64 yr olds has been ongoing since 1995. Greater than 3400 primary and 1000 follow up screening examinations have been performed. Participants with a primary screen in 1997–1999 and eligible for rescreening in 2002–2004 were studied. A questionnaire assessing possible reasons for noncompliance was sent to subjects who did not attend the five year repeat screening.

Results: 1672 primary screening flexible sigmoidoscopies were performed in 1997–1999 with 1362 being normal or having hyperplastic polyps only. The return rate was 45%: 48% of eligible males and 39% of eligible females had returned (p = 0.001 for difference). 709 questionnaires were mailed with a 50% response rate and 162 requests for repeat flexible sigmoidoscopy were generated. 27% of all respondents had undergone further bowel evaluation since the original normal sigmoidoscopy. Of eligible subjects who refused further screening, 65% did so because of concerns over procedural pain.

Conclusions: Reasons for nonattendance relate to uptake of other bowel investigations and pain felt at initial screening. Return rate can be raised with ongoing prompting to attend screening.

Keywords: sigmoidoscopy, colonoscopy, colonic neoplasm, population surveillance, patient compliance


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

Taha H, Das A, Das S

Infection and Drug Resistance 2015, 8:339-352

Published Date: 1 October 2015

Polyhydroxylated fullerene attenuates oxidative stress-induced apoptosis via a fortifying Nrf2-regulated cellular antioxidant defence system

Ye SF, Chen M, Jiang YQ, Chen ML, Zhou T, Wang YG, Hou ZQ, Ren L

International Journal of Nanomedicine 2014, 9:2073-2087

Published Date: 29 April 2014

Association study of IGF1 polymorphisms with susceptibility to high myopia in a Japanese population

Yoshida M, Meguro A, Yoshino A, Nomura N, Okada E, Mizuki N

Clinical Ophthalmology 2013, 7:2057-2062

Published Date: 16 October 2013

Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging

Jie L-Y, Cai L-L, Wang L-J, Ying X-Y, Yu R-S, Zhang M-M,Du Y-Z

International Journal of Nanomedicine 2012, 7:3981-3989

Published Date: 24 July 2012

Acute whiplash associated disorders (WAD)

Pastakia K, Kumar S

Open Access Emergency Medicine 2011, 3:29-32

Published Date: 27 April 2011

Brief report: Characteristics of antidepressant use in patients with heart failure

Paul J Mills, Joel E Dimsdale, Suzi Hong, Geoffrey Van Den Brande, Laura Redwine, et al

Patient Preference and Adherence 2008, 2:333-336

Published Date: 11 November 2008

Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain

Nicole Rae Yurgin, Kristina Secnik Boye, Tatiana Dilla, Núria Lara Suriñach, Xavier Badia Llach

Patient Preference and Adherence 2008, 2:87-95

Published Date: 8 April 2008

Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program

Susan M Abughosh, Stephen J Kogut

Patient Preference and Adherence 2008, 2:79-85

Published Date: 20 March 2008